Liquid biopsy is moving rapidly from a promising research tool into an increasingly important component of oncology practice. Its applications across early detection, disease monitoring and treatment response are expanding as technologies mature and clinical evidence grows.
At the same time, Liquid Biopsy Webinar ONLINE – Unlocking the Ability to Transform Cancer Care, translating these advances into routine use remains challenging. Questions remain around when to use it, how to interpret results, and how to integrate these approaches into clinical workflows, trials, and decision-making
This three-part webinar series brings together leading experts to explore where the field is today, how it is being applied in practice, and what still needs to be solved to support broader clinical adoption.
With thanks to our series sponsor, Integrated DNA Technologies (IDT)
This webinar series is CPD certified: this is your chance to learn and earn up to 3 CPD points.
Please note that by registering for one webinar in the series, you will automatically gain access to the subsequent webinars.
Webinar 1: Breakthrough technologies and multi-omic innovations: Where are we now?
Thursday 7th May 2026 at 3pm BST / 4pm CEST / 10am EDT
Detecting cancer earlier – while it is still treatable – remains a central goal of modern liquid biopsy research. This session explores the latest advances in liquid biopsy technologies and multi-omic approaches, and how they are beginning to translate into clinical practice.
By attending this webinar, you will:
- Gain an update on emerging liquid biopsy technologies and multi-omic biomarker approaches
- See how novel analytes are enabling ultra-sensitive detection
- Learn how MRD is used to identify patients at highest risk of relapse
- Understand current barriers to adoption, including data harmonisation and regulatory expectations around novel endpoints
Talk 1: A toolkit to evaluate candidate early detection biomarkers
- Christopher Douville, Assistant Professor, Johns Hopkins University
Talk 2: Get more from every specimen: How Archer AMP™ detects variants from challenging inputs
- Karthik Ganapathy, Sr. Commercial Product Manager, NGS Solutions, Integrated DNA Technologies
- Elina Wegner, Director of Product Innovation, NGS Solutions, Integrated DNA Technologies
Talk 3: Histone-based liquid biopsy for monitoring non-communicable diseases
- Manlio Vinciguerra, Principal Investigator and Professor, Research Institute of the Medical University of Varna, Bulgaria

Webinar 2: Minimal residual disease – Transforming surveillance & treatment planning
Thursday 14th May 2026 at 3pm BST / 4pm CEST / 10am EDT
Minimal residual disease (MRD) is becoming central to relapse prediction, risk stratification, and treatment planning across both haematological and solid tumours. This session explores how advances in ultra-sensitive assays, computational methods and ctDNA analysis are shaping clinical decision-making and trial design.
By attending this webinar, you will:
- Explore advances in high-resolution MRD assessment in AML and solid tumours
- Understand how machine learning is supporting analysis of flow cytometry and plasma-only ctDNA assays
- Learn how ctDNA-defined MRD is informing treatment escalation, de-escalation, and clinical trial endpoints
- Gain insight into how MRD and early detection data are linking to stage shift and potential reductions in cancer mortality
Talk 1: MRD assessment: From expert gating to AI-supported clinical decision-making in AML
- Costa Bachas, Research Associate Haematology/Oncology, Amsterdam University Medical Center
Talk 2: Optimizing high-sensitivity NGS workflows for ultra-low-frequency variant detection in minimal residual disease research
- David Knupp, Staff Scientist, Integrated DNA Technologies
Talk 3: MRD-guided treatment: Using ctDNA to stratify risk, select patients and shape endpoints
- Aparna Parikh, Associate Professor, Harvard Medical School
Talk 4: Can liquid biopsy reduce cancer mortality? What the evidence shows
- Jagpreet Chhatwal, Associate Professor, Harvard Medical School

Webinar 3: Adaptive oncology – How liquid biopsies can guide treatment decisions: Demonstrating real patient benefit
Thursday 21st May 2026, at 3pm BST / 4pm CEST / 10am EDT
Real-time monitoring of patient response is critical for decisions such as switching therapies, de-escalation and early detection of resistance. This session focuses on how ctDNA and broader cfDNA approaches are being used in clinical research and drug development to enable more adaptive, personalised treatment strategies.
By attending this webinar, you will:
- Understand how ctDNA and CTC analyses are being integrated into trial design and clinical practice
- Gain insight into the technical limitations of liquid biopsy for treatment monitoring – and how they impact decisions
- Explore the role of cfDNA as a prognostic biomarker and predictor of patient response
- Learn how these approaches are shaping the future of personalised and adaptive oncology
Talk 1: From clinical trial investigation to clinical implementation of liquid biopsies in colorectal cancer
- Giorgio Patelli, Medical Oncologist, IFOM
Talk 2: Monitoring drug efficacy by ctDNA: When, how and why?
- Darren Hodgson, Executive Director of Cancer Biomarker Development, AstraZeneca
Talk 3: The promise of cfDNA in drug development: From prognostic biomarker to early PD readout and beyond
- Christina Godfried Sie, Senior Scientist, Roche





